Invivyd Inc. (ADGI) NASDAQ
$4.83 - (-)
Market Cap: $525.65M
As of 09/13/22 12:00 AM EDT. Market closed.
Invivyd Inc. (ADGI)
NASDAQ
$4.83
- (-)
Market Cap: $525.65M
As of 09/13/22 12:00 AM EDT. Market closed.
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful ... read more
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. read less
Open in: 
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Adimab, LLC | 10% Owner | Jan 19, 2024 | Sale | $3.95 | 5,000,000 | 19,750,000 | 21,687,906 | Jan 22, 2024, 04:18 PM |
| Hering David | Chief Executive Officer | Sep 01, 2022 | Buy | $4.52 | 8,000 | 36,160 | 8,000 | Sep 01, 2022, 04:28 PM |
| Elia Marc | Director | Aug 19, 2022 | Buy | $4.62 | 584,451 | 2,700,164 | 9,248,250 | Aug 19, 2022, 04:57 PM |
| Elia Marc | Director | Aug 18, 2022 | Buy | $4.31 | 1,265,549 | 5,454,516 | 8,663,799 | Aug 19, 2022, 04:57 PM |
| Elia Marc | Director | Aug 17, 2022 | Buy | $4.04 | 1,000,000 | 4,040,000 | 7,398,250 | Aug 19, 2022, 04:57 PM |
| Royan Ajay | Director | Aug 10, 2021 | Buy | $17.00 | 1,997,000 | 33,949,000 | 11,241,580 | Aug 12, 2021, 09:27 PM |
| MITHRIL II LP | 10% Owner | Aug 10, 2021 | Buy | $17.00 | 1,997,000 | 33,949,000 | 11,241,580 | Aug 12, 2021, 09:25 PM |
| MCGUIRE TERRANCE | Director | Aug 10, 2021 | Buy | $17.00 | 500,000 | 8,500,000 | 4,800,460 | Aug 12, 2021, 09:24 PM |
| Redmile Group, LLC | 10% Owner | Aug 10, 2021 | Buy | $17.00 | 1,470,000 | 24,990,000 | 3,390,960 | Aug 12, 2021, 09:01 PM |
| Owner | Relationship | Date | Value($) |
| Adimab, LLC | 10% Owner | 01/19/2024 | 19,750,000 |
| Hering David | Chief Executive Officer | 09/01/2022 | 36,160 |
| Elia Marc | Director | 08/19/2022 | 2,700,164 |
| Elia Marc | Director | 08/18/2022 | 5,454,516 |
| Elia Marc | Director | 08/17/2022 | 4,040,000 |
| Royan Ajay | Director | 08/10/2021 | 33,949,000 |
| MITHRIL II LP | 10% Owner | 08/10/2021 | 33,949,000 |
| MCGUIRE TERRANCE | Director | 08/10/2021 | 8,500,000 |
| Redmile Group, LLC | 10% Owner | 08/10/2021 | 24,990,000 |
Period of Report: 12/31/2023
10-K/10-Q Filings: View